HALOZYME THERAPEUTICS, INC. HALO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
5/9
Piotroski F — financial health
3.02
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.4B | $316.9M | — | $644.6M | $48.8M |
| 2024 | $1.0B | $444.1M | — | $468.4M | $363.8M |
| 2023 | $829.3M | $281.6M | — | $373.3M | $83.8M |
| 2022 | $660.1M | $202.1M | — | $235.3M | $169.8M |
| 2021 | $443.3M | $402.7M | — | $298.0M | $197.0M |
| 2020 | $267.6M | $129.1M | — | $53.0M | $151.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | 2026-06-12 | Option exercise | 5,034 | — |
| Snyder Mark Howard | SVP, CHIEF LEGAL OFFICER | 2026-06-12 | Tax withheld | 2,715 | $69.50 |
| Torley Helen | PRESIDENT AND CEO | 2026-06-03 | Sell | 6,100 | $69.69 |
| Torley Helen | PRESIDENT AND CEO | 2026-06-03 | Sell | 1,500 | $67.67 |
| Torley Helen | PRESIDENT AND CEO | 2026-06-03 | Option exercise | 10,000 | $12.07 |
| Torley Helen | PRESIDENT AND CEO | 2026-06-03 | Sell | 400 | $66.37 |
| Torley Helen | PRESIDENT AND CEO | 2026-06-03 | Sell | 2,000 | $68.74 |
| Torley Helen | PRESIDENT AND CEO | 2026-06-02 | Option exercise | 20,000 | $12.07 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 3.02 (safe)
- Working capital / assets 0.257
- Retained earnings / assets 0.022
- EBIT / assets 0.186
- Equity / liabilities 0.02
Source: SEC EDGAR filings · CIK 0001159036 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.